| Literature DB >> 32085740 |
Frank Chinowaita1,2,3, Wendy Chaka4, Tinashe K Nyazika5,6,7, Tendai C Maboreke8, Emmanuel Tizauone4,9, Prichard Mapondera10, Inam Chitsike11, Andrew Z Cakana8, Rooyen T Mavenyengwa4.
Abstract
BACKGROUND: Cancer and sepsis comorbidity is a major public health problem in most parts of the world including Zimbabwe. The microbial aetiologies of sepsis and their antibiograms vary with time and locations. Knowledge on local microbial aetiologies of sepsis and their susceptibility patterns is critical in guiding empirical antimicrobial treatment choices.Entities:
Keywords: Aetiology; Antimicrobial resistance; Cancer; ESBL; Sepsis
Year: 2020 PMID: 32085740 PMCID: PMC7035672 DOI: 10.1186/s12879-020-4886-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Study population demographic characteristics
| Characteristic | Total | Haematological neoplasm | Solid tumour |
|---|---|---|---|
| Female | 76 (53.5) | 58 (76.3) | 18 (23.7) |
| Age median (IQR) years | – | 15 (4–34) | 6 (5–10) |
| Paediatric (oncology ward) | 86 | 55 (64.0) | 31 (36.0) |
| Adults (oncology ward) | 1 | – | 1 (100.0) |
| Adult (haematology ward) | 55 | 55 (100.0) | – |
| Hospital stay median (IQR) days | 7.0 (4–15) | 7.0 (4–15) | 7.5 (3–13) |
| Neutropenia | 44 (31.0) | 42 (39.1) | 1 (3.1) |
n, number
Distribution of sepsis causing pathogens in participants with cancer
| Causative pathogen | Number of isolates ( | Total (%) | |||
|---|---|---|---|---|---|
| Haematological neoplasm | Solid tumour | ||||
| Children | Adults | Children | adults | ||
| Gram-negative bacteria ( | |||||
| | 4 | 2 | 2 | – | 8 (16.0) |
| | 2 | 3 | 2 | – | 7 (14.0) |
| | 1 | – | – | 1 (2.0) | |
| | – | 1 | – | – | 1 (2.0) |
| | 1 | – | – | – | 1 (2.0) |
| | 1 | – | – | – | 1 (2.0) |
| | – | 1 | – | – | 1 (2.0) |
| | – | – | 1 | – | 1 (2.0) |
| Gram positive bacteria ( | |||||
| CoNS | 3 | 6 | 2 | – | 11 (22.0) |
| | 2 | 1 | – | 1 | 4 (8.0) |
| | 1 | 5 | 1 | – | 7 (14.0) |
| | 2 | – | – | – | 2 (4.0) |
| | 1 | – | – | – | 1 (2.0) |
| | 0 | 1 | 2 | – | 3 (6.0) |
| Fungi ( | |||||
| | 1 | – | – | – | 1 (2.0) |
n, number
Distribution of antimicrobial susceptibility patterns for gram negative isolates
| Bacterial isolates | N | AMP | PTZ | CXM | CRO | CAZ | CEF | FOX | GM | AK | CIP | LEV | MEM | COT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | 1 | 7 | 2 | 2 | 2 | 4 | 7 | 2 | 8 | 2 | 2 | 8 | 0 | |
| 7 | 0 | 4 | 2 | 2 | 2 | 4 | 6 | 3 | 7 | 3 | 4 | 7 | 1 | |
| 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | |
| 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | |
| 1 | – | 1 | – | 0 | 1 | 1 | – | 1 | 1 | 1 | 1 | 1 | 0 | |
| 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |
| Total |
Notes: AMP Ampicillin, PTZ Piperacillin-tazobactam, CRO Ceftriaxone, CAZ Ceftazidime, CXM Cefuroxime, CEF Cefepime, FOX Cefoxitin, GM Gentamicin, AK Amikacin, CIP ciprofloxacin, LEV Levofloxacin, COT Trimethoprim-sulfamethoxazole, MEM Meropenem; N Number; (−), not tested, (0), zero sensitive isolates
Distribution of drug susceptible Staphylococcus species
| Bacterial species isolates | N | VA | LIN | ERY | CD | TET | MINO | RIF | GM | CIP | PEN | COT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 4 | 4 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 0 | 2 | |
| 11 | 11 | 11 | 7 | 7 | 5 | 9 | 8 | 6 | 5 | 1 | 6 | |
| Total sensitive |
Notes: VA Vancomycin, LIN Linezolid, ERY Erythromycin, CD Clindamycin, TET Tetracycline, MINO Minocycline, RIF Rifampicin, CHL Chloramphenicol, CIP Ciprofloxacin, GM Gentamicin, PEN Penicillin, COT Trimethoprim-sulfamethoxazole, N Number; (0), zero susceptible isolates
Antimicrobial susceptibility patterns for Streptococcus and Enterococcus species
| Bacterial isolates | N | AMP | PEN | VA | LINE | FOSF | GM | TET | CIP | LEV | GATI |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 7 | 7 | 7 | 7 | 7 | 6 | 2 | 4 | 4 | 4 | |
| 2 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | |
| 3 | 1 | 1 | 2 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | |
| Total |
Notes: AMP Ampicillin, PEN Penicillin, VA Vancomycin, LINE Linezolid, FOSF Fosfomycin, GM Gentamicin, TET Tetracycline, LEV Levofloxacin, CIP Ciprofloxacin, GATI Gtifloxacin, N Number, (0), zero sensitive isolates